Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research

Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

Please add ResearchGrants@BrightFocus.org to your institution’s white list to insure that the notification is not blocked by your organization’s SPAM filters.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research


Macular Degeneration Research
Completed Award

Dr. Jeffrey Stern

Jeffrey Stern, M.D., Ph.D.

Regenerative Research Foundation
Rensselaer, NY

Title: alphaB-crystallin and the Amyloid-beta mediated RPE stress response in Age related Macular Degeneration
Non-Technical Title: The role of Alzheimer Disease protein and the stress response in AMD

Duration: April 1, 2008 - May 31, 2010
Award Type: Standard
Award Amount: $100,000


A protein related to Alzheimer's disease is known to be present in cases of AMD. This proposal will examine a toxic product of this protein and ask whether it is involved in the development of AMD.


Researchers have discovered that a protein present in the Alzheimer's diseased brain is also present in the back of the eye (the retina) of patients with AMD. These scientists have found that a second protein, alphaB-crystallin, is also present. These two proteins can bind together to produce a compound that can be toxic to nervous system cells and promote the growth of blood vessels. Both of these processes could stimulate AMD progression.This study will examine whether these proteins interact in AMD and whether this interaction has a detrimental effect. They will alter the levels of each of these proteins to see if doing so improves the health of retinal cells. Finally, they will test a potential new drug for AMD that lowers the Alzheimer's disease protein to see if it also improves the health of human retinal cells. If these culture studies are successful, they could pave the way toward future clinical trials.